Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB) (click to learn more) AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Annexon Inc ANNX

Healthcare Biotechnology
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company’s lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and... see more

Current News (NDAQ:ANNX)

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

GlobeNewswire 1 day ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 16, 2026

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

GlobeNewswire January 12, 2026

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

GlobeNewswire January 8, 2026

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2026

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 16, 2025

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

GlobeNewswire November 14, 2025

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 12, 2025

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 12, 2025
View More News ››

Opinion & Analysis (NDAQ:ANNX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ANNX)

Be the first to post on this bullboard.

Sekur Private Data Ltd.

Sekur Private Data Ltd.

Sekur Private Data Ltd. operates as a cybersecurity and internet privacy provider of Swiss hosted solutions for secure ...
View More »

Podcasts